FIELD: medicine； pharmaceuticals.SUBSTANCE: group of inventions refers to monoclonal antibodies directed to epitopes detected within lipoarabinomannan (LAM) for diagnosis and treatment of infections caused by Mycobacterium tuberculosis. Disclosed is a human monoclonal antibody to lipoarabinomannan (to LAM) or its antigen-binding portion, which specifically bind to LAM epitope, containing an Ara4 structure, an Ara6 structure or a combination thereof, wherein the LAM antibody comprises a light chain variable region CDR1 characterized by at least 80 % identity with SEQ ID NO: 1 or antigen fragments thereof, CDR2 of the light chain variable region, characterized by at least 80 % identity with SEQ ID NO: 2 or its antigen fragments, light chain variable region CDR3, characterized by at least 80 % identity with SEQ ID NO: 3 or SEQ ID NO: 26 or their antigen fragments, heavy chain variable region CDR1, characterized by at least 80 % identity with SEQ ID NO: 4 or its antigen fragments, heavy variable domain variable region CDR2, characterized by at least 80 % identity with SEQ ID NO: 5 or its antigen fragments, and CDR3 of heavy chain variable region, characterized by at least 80 % identity with SEQ ID NO: 6 or SEQ ID NO: 23 or their antigen fragments. Also disclosed is a kit for detecting at least one epitope of LAM, a method for diagnosing active tuberculosis infection in an individual and a method of treating tuberculosis infection in an individual.EFFECT: group of inventions provides effective treatment and diagnosis of tuberculosis infection.15 cl, 32 dwg, 4 tbl, 2 exГруппа изобретений относится к моноклональным антителам, направленным на эпитопы, обнаруживаемые в пределах липоарабиноманнана (LAM), для диагностики и лечения инфекций, вызванных Mycobacterium tuberculosis. Раскрыто человеческое моноклональное антитело к липоарабиноманнану (к LAM) или его антигенсвязывающая часть, которые специфически связываются с эпитопом LAM, содержащим структуру Ara4, структуру Ara6 ил
